Aridis Pharmaceuticals, Inc. (ARDS)
OTCMKTS: ARDS · Delayed Price · USD
0.0614
-0.0001 (-0.16%)
May 6, 2024, 9:52 AM EDT - Market open
Aridis Pharmaceuticals Revenue
Aridis Pharmaceuticals had revenue of $20.06M in the twelve months ending September 30, 2023, with 2,227.61% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $417.00K.
Revenue (ttm)
$20.06M
Revenue Growth
+2,227.61%
P/S Ratio
0.14
Revenue / Employee
$542,270
Employees
37
Market Cap
2.74M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 1.00M | -22.00K | -2.15% |
Dec 31, 2019 | 1.02M | -1.74M | -62.93% |
Dec 31, 2018 | 2.76M | 1.90M | 220.58% |
Dec 31, 2017 | 860.00K | -1.41M | -62.10% |
Dec 31, 2016 | 2.27M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 81.80B |
Merck & Co. | 60.12B |
AbbVie | 54.40B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
ARDS News
- 5 months ago - Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024 - GlobeNewsWire
- 6 months ago - Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update - GlobeNewsWire
- 9 months ago - Aridis Pharmaceuticals Announces $2 Million Offering - GlobeNewsWire
- 10 months ago - Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301 - GlobeNewsWire
- 10 months ago - Aridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) Designation - GlobeNewsWire
- 11 months ago - Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - Accesswire
- 11 months ago - Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update - GlobeNewsWire
- 1 year ago - Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q - GlobeNewsWire